<DOC>
	<DOCNO>NCT00727129</DOCNO>
	<brief_summary>The purpose study compare safety efficacy USL-221 placebo postmenopausal patient .</brief_summary>
	<brief_title>Study Evaluate Divigel Treatment Postmenoupausal Symptoms</brief_title>
	<detailed_description />
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Postmenopausal woman Have moderate severe hot flash Normal Pap Smear Abnormal mammogram Abnormal clinical breast exam BMI &gt; 35</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>vasomotor symptom</keyword>
	<keyword>estrogen</keyword>
	<keyword>estradiol</keyword>
	<keyword>hot flash</keyword>
</DOC>